Johnson & Johnson (NYSE:JNJ – Get Free Report) released its earnings results on Wednesday. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.85 by $0.05, FiscalAI reports. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.02 billion. Johnson & Johnson updated its FY 2026 guidance to 11.600-11.750 EPS.
Johnson & Johnson Price Performance
NYSE JNJ opened at $253.70 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $610.71 billion, a price-to-earnings ratio of 29.33, a PEG ratio of 2.46 and a beta of 0.24. Johnson & Johnson has a one year low of $154.80 and a one year high of $269.43. The stock has a 50-day moving average of $238.18 and a 200 day moving average of $233.92.
Analysts Set New Price Targets
JNJ has been the subject of several research reports. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. TD Cowen lifted their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday. Stifel Nicolaus lifted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Finally, Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $261.26.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.
Institutional Trading of Johnson & Johnson
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Semmax Financial Advisors Inc. raised its position in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Turning Point Benefit Group Inc. acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $41,000. Safe Harbor Fiduciary LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $50,000. Imprint Wealth LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $47,000. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $80,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson News Roundup
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Johnson & Johnson reported Q2 results that beat Wall Street estimates, helped by strong performance in its medicines business, including Tremfya and Darzalex. Reuters article
- Positive Sentiment: The company raised FY 2026 EPS guidance to 11.60-11.75, slightly above consensus, and increased revenue guidance to $100.8 billion-$101.4 billion, signaling continued operational momentum. Business Wire article
- Positive Sentiment: Johnson & Johnson also declared a quarterly dividend of $1.34 per share, reinforcing its appeal as a defensive income stock. Business Wire dividend article
- Neutral Sentiment: Several pre-earnings previews had already highlighted J&J’s strong share performance and the chance for the stock to extend gains if results came in cleanly, which may have set a high bar. Barron’s article
- Negative Sentiment: Despite the beat and raised outlook, the stock slipped as investors appeared to take profits and react to limited upside versus already elevated expectations. Barron’s article
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet
- Marriott vs. Viking: Why the Better Quarter Doesn’t Mean the Better Decade
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
